Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT07226557
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
Sponsor: National Institutes of Health Clinical Center (CC)
View on ClinicalTrials.gov
Summary
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
5000
Start Date
2025-01-01
Completion Date
2025-12-31
Last Updated
2025-11-10
Healthy Volunteers
No
Conditions
Locations (1)
National Institutes of Health Clinical Center
Bethesda, Maryland, United States